Member Companies

Priorities

Greater Flexibility

Greater flexibility in regulatory approval requirements is needed to incentivize investment in novel antimicrobial and diagnostic device development. Policy options that strike an appropriate balance between safety, efficacy, and urgent needs in public health should be explored by industry together with both the FDA and other key stakeholders.

Alternative Pricing Models

Alternative pricing models must be explored to help improve the economic conditions surrounding antimicrobial and diagnostic device development and generate a robust antimicrobials pipeline.

Work With Experts

AWG is also eager to work with subject matter experts, community members, advocates, and organizations that seek to support and expedite the development of antimicrobial drugs and diagnostic devices.

“Innovation is the calling card of the future”

– Congresswoman Anna Eshoo

AMR Stories

AWG Executive Committee

Evan Loh, M.D.

Chairman of the AWG Board
Chair, AWG Chemistry, Manufacturing
and Controls(CMC) Subcommittee
Chief Executive Officer
Paratek Pharmaceuticals, Inc.

full bio

Michael Dunne, M.D

AWG Vice Chair
Chief Scientific Officer
Iterum Therapeutics

full bio

Ciara Kennedy, Ph.D.

Chair, AWG Antifungal Subcommittee
President and Chief Executive Officer
Amplyx Pharmaceuticals, Inc.

full bio

Ted Schroeder

Chief Executive Officer
Nabriva Therapeutics

full bio

Jeffrey Stein, Ph.D.

President and Chief Executive Officer
Cidara Therapeutics

full bio

Latest AWG News